Table 2.
Hematological, biochemical, and clinical variables of 218 patients with ET according to sTXB2 quartiles
| Quartiles | P value | ||||
|---|---|---|---|---|---|
|
1st < 9.1 ng/mL N = 57 |
2nd 9.1–19 ng/mL N = 56 |
3rd 19.3–42 ng/mL N = 50 |
4th > 42 ng/mL N = 55 |
||
| Sex | |||||
| Male, n (%) | 23 (40.4) | 27 (48.2) | 25 (50.0) | 29 (52.7) | 0.593 |
| Female, n (%) | 34 (59.6) | 29 (51.8) | 25 (50.0) | 26 (47.3) | |
| Age at enrollment, years | 63.0 [54.0; 69.0] | 64.0 [56.0; 69.0] | 58.0 [50.0; 66.8] | 56.5 [49.0; 62.0] | 0.006 |
| Body mass index, kg/m2 | 24.5 [22.1; 27.7] | 25.5 [23.1; 26.9] | 25.0 [23.0; 27.0] | 24.6 [21.7; 27.0] | 0.626 |
| Leukocytes, ×109/L | 6.93 [5.5; 8.2] | 6.90 [5.8; 8.2] | 6.54 [5.5; 7.6] | 7.69 [6.8; 9.0] | 0.019 |
| Platelets, ×109/L | 451 [397; 500] | 520 [405; 598] | 528 [460; 625] | 641 [482; 772] | < 0.001 |
| Hematocrit, % | 40.3 [38.4; 43.6] | 41.7 [39.3; 44.2] | 40.7 [38.7; 43.6] | 43.8 [41.5; 46.0] | < 0.001 |
| JAK2‐V617F | |||||
| Wild type, n (%) | 30 (52.6) | 26 (46.4) | 18 (36.0) | 15 (27.3) | 0.034 |
| Mutated, n (%) | 27 (47.4) | 30 (53.6) | 32 (64.0) | 40 (72.7) | |
| CALR | |||||
| Type 1, n (%) | 7 (21.9) | 7 (21.2) | 2 (7.69) | 3 (12.0) | 0.127 |
| Type 2, n (%) | 4 (12.5) | 6 (18.2) | 5 (19.2) | 0 (0.00) | |
| Other, a n (%) | 21 (65.6) | 20 (60.6) | 19 (73.1) | 22 (88.0) | |
| Cytoreduction | |||||
| No, n (%) | 13 (22.8) | 16 (28.6) | 19 (38.0) | 36 (65.5) | <0.001 |
| Yes, n (%) | 44 (77.2) | 40 (71.4) | 31 (62.0) | 19 (34.5) | |
| Microvascular symptoms | |||||
| No, n (%) | 52 (91.2) | 51 (91.1) | 45 (90.0) | 46 (83.6) | 0.532 |
| Yes, n (%) | 5 (8.8) | 5 (8.9) | 5 (10.0) | 9 (16.4) | |
| Thrombosis | |||||
| No, n (%) | 55 (96.5) | 53 (94.6) | 49 (98.0) | 52 (94.5) | 0.833 |
| Yes, n (%) | 2 (3.5) | 3 (5.4) | 1 (2.00) | 3 (5.5) | |
| IPSET score | |||||
| 0, n (%) | 8 (14.0) | 7 (12.5) | 7 (14.0) | 6 (10.9) | |
| 1, n (%) | 15 (26.3) | 12 (21.4) | 6 (12.0) | 5 (9.09) | |
| 2, n (%) | 15 (26.3) | 13 (23.2) | 17 (34.0) | 23 (41.8) | |
| 3, n (%) | 3 (5.26) | 12 (21.4) | 13 (26.0) | 12 (21.8) | |
| 4, n (%) | 15 (26.3) | 10 (17.9) | 7 (14.0) | 7 (12.7) | |
| 5, n (%) | 1 (1.8) | 2 (3.4) | 0 (0.0) | 1 (1.8) | |
| 6, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.8) | |
| Primary prophylaxis | |||||
| No, n (%) | 7 (12.3) | 7 (12.5) | 6 (12.0) | 11 (20.0) | 0.568 |
| Yes, n (%) | 50 (87.7) | 49 (87.5) | 44 (88.0) | 44 (80.0) | |
| Urinary TXM, pg/mg creatinine | 436 (176) | 492 (232) | 443 (223) | 680 (555) | < 0.001 |
Values are median and [IQR] or frequency and (percentages). P values are from median and chi‐square test, respectively.
IPSET, International Prognostic Score of Thrombosis for Essential Thrombocythemia; TXM, urinary 11‐dehydro‐TxB2.
a
Includes the following detected genotypes: CALR‐negative, CALR mutations other than type I or type II and MPL mutations. CALR was not genotyped in 115 patients (102 in the compliant group, 13 in the not compliant group).